ALFA Filings
Every announcement, straight from the exchange
Every Venmax Drugs & Pharmaceuticals other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI LODR Regulations for the quarter ended September 30, 2026.
Venmax Drugs and Pharmaceuticals Limited filed a statement confirming no deviation or variation in the utilization of proceeds from its previous preferential issue.
Venmax Drugs and Pharmaceuticals Limited informed BSE that it is exempt from submitting the Annual Secretarial Compliance Report for the year ended March 31, 2026. The exemption applies as the company's paid-up capital and net worth remain below the regulatory thresholds specified under Regulation 15(2) of SEBI (LODR) Regulations 2015.
Venmax Drugs and Pharmaceuticals Ltd promoter, Venkat Narender Nuka, submitted the annual SEBI (SAST) declaration for FY 2025-26. The promoter confirmed holding 9,26,775 shares and stated that no encumbrances or pledges were made on these shares during the period.